BR0110659A - Composição farmacêutica, kit, uso de um fator viia em combinação com um fator, xiii, e, métodos para intensificação da formação de coágulo de fibrina em um indivìduo e para tratar de episódios de hemorragia em um indivìduo - Google Patents

Composição farmacêutica, kit, uso de um fator viia em combinação com um fator, xiii, e, métodos para intensificação da formação de coágulo de fibrina em um indivìduo e para tratar de episódios de hemorragia em um indivìduo

Info

Publication number
BR0110659A
BR0110659A BR0110659-7A BR0110659A BR0110659A BR 0110659 A BR0110659 A BR 0110659A BR 0110659 A BR0110659 A BR 0110659A BR 0110659 A BR0110659 A BR 0110659A
Authority
BR
Brazil
Prior art keywords
individual
factor
xiii
kit
pharmaceutical composition
Prior art date
Application number
BR0110659-7A
Other languages
English (en)
Inventor
Lars Christian Petersen
Ulla Hedner
Rasmus Rojkjaer
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR0110659A publication Critical patent/BR0110659A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA, KIT, USO DE UM FATOR VIIa EM COMBINAçãO COM UM FATOR XIII, E, MéTODOS PARA INTENSIFICAçãO DA FORMAçãO DE COáGULO DE FIBRINA EM UM INDIVìDUO E PARA TRATAR DE EPISóDIOS DE HEMORRAGIA EM UM INDIVìDUO". A presente invenção diz respeito ao uso de um fator VIIa e um fator XIII no tratamento ou profilaxia de episódios de hemorragia.
BR0110659-7A 2000-05-10 2001-05-10 Composição farmacêutica, kit, uso de um fator viia em combinação com um fator, xiii, e, métodos para intensificação da formação de coágulo de fibrina em um indivìduo e para tratar de episódios de hemorragia em um indivìduo BR0110659A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200000778 2000-05-10
DKPA200000771 2000-05-10
DKPA200000871 2000-06-06
PCT/DK2001/000322 WO2001085198A1 (en) 2000-05-10 2001-05-10 tHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIA AND A FACTOR XIII

Publications (1)

Publication Number Publication Date
BR0110659A true BR0110659A (pt) 2003-02-11

Family

ID=27222387

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110659-7A BR0110659A (pt) 2000-05-10 2001-05-10 Composição farmacêutica, kit, uso de um fator viia em combinação com um fator, xiii, e, métodos para intensificação da formação de coágulo de fibrina em um indivìduo e para tratar de episódios de hemorragia em um indivìduo

Country Status (17)

Country Link
US (3) US20030092627A1 (pt)
EP (3) EP1282438B1 (pt)
JP (2) JP2004505016A (pt)
CN (1) CN1304049C (pt)
AT (2) ATE300953T1 (pt)
AU (3) AU5822801A (pt)
BR (1) BR0110659A (pt)
CA (1) CA2406583A1 (pt)
CZ (1) CZ20023667A3 (pt)
DE (2) DE60115422T2 (pt)
DK (1) DK1282438T3 (pt)
ES (2) ES2254414T3 (pt)
HU (1) HUP0301868A3 (pt)
IL (1) IL152554A0 (pt)
NO (1) NO20025355L (pt)
PL (1) PL365042A1 (pt)
WO (2) WO2001085199A1 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1245216C (zh) * 1999-10-04 2006-03-15 希龙公司 稳定化的含多肽的液体药物组合物
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
ES2429523T3 (es) 2000-09-13 2013-11-15 Novo Nordisk Health Care Ag Variantes del factor VII de coagulación humana
EP2226385B1 (en) * 2000-09-13 2013-07-10 Novo Nordisk Health Care AG Human Coagulation Factor VII Variants
WO2002036155A1 (en) * 2000-11-03 2002-05-10 Zymogenetics, Inc. Use of blood coagulation factor xiii for treating haemophilia a
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
DE60129599T2 (de) * 2000-11-10 2008-04-17 Zymogenetics, Inc., Seattle Faktor xiii in kombination mit faktor ix zur behandlung von hämophilie b
AU2002229510A1 (en) * 2001-02-05 2002-08-19 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor viii polypeptides
US6979445B2 (en) * 2001-02-21 2005-12-27 Zymogenetics, Inc Method for treating von willebrand's disease
US7115559B2 (en) * 2001-09-10 2006-10-03 Zymogenetics Inc. Method for treating coumarin-induced hemorrhage
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
EP1446147A1 (en) * 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Pharmaceutical composition comprising factor vii polypeptides and tranexamic acid
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
US7291587B2 (en) 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
EP1446148A1 (en) * 2001-11-09 2004-08-18 Novo Nordisk A/S Pharmaceutical composition comprising a factor vii polypeptide and epsilon-aminocapronic acid
CN101675991A (zh) * 2001-12-21 2010-03-24 诺和诺德医疗保健公司 因子ⅶ多肽的液体组合物
ATE428439T1 (de) * 2001-12-21 2009-05-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzung aus faktor vii polypeptiden
PT1517698E (pt) 2002-06-21 2014-11-19 Novo Nordisk Healthcare Ag Composições sólidas estabilizadas de polipéptidos do fator viia
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
EA008038B1 (ru) 2003-01-08 2007-02-27 Чирон Корпорейшн Стабилизированные водные композиции, содержащие ингибитор пути метаболизма, тканевого фактора (tfpi) или вариант ингибитора пути метаболизма тканевого фактора
WO2004112828A1 (en) 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
JP5653572B2 (ja) 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
ES2381110T3 (es) 2003-09-09 2012-05-23 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación
WO2005107795A1 (en) * 2004-05-11 2005-11-17 Novo Nordisk Health Care Ag Use of factor viia for the treatment of burn traumas
WO2005115442A1 (en) * 2004-05-25 2005-12-08 Novo Nordisk Health Care Ag Use of coagulation factor xiii for treatment of post surgical bleedings
EP1784415A2 (en) * 2004-08-27 2007-05-16 Novo Nordisk Health Care AG Purification of factor xiii polypeptides from biological materials
WO2006026998A1 (en) * 2004-09-10 2006-03-16 Pharmaorigin Aps Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis
AU2005308830B2 (en) 2004-11-23 2012-01-19 Zymogenetics, Inc. Purification of recombinant human factor XIII
US20090130086A1 (en) * 2005-02-28 2009-05-21 Novo Nordisk Health Care Ag FXIII Variants with Improved Properties
EP1919499A2 (en) * 2005-07-29 2008-05-14 Universiteit van Maastricht Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor
WO2007104317A1 (en) * 2006-03-16 2007-09-20 Drugrecure Aps Methods for local treatment with factor vii
JP5122562B2 (ja) * 2006-07-17 2013-01-16 ノボ ノルディスク ヘルス ケア アーゲー 増加した活性を有する第ｖｉｉａ因子アナログの新規用途
US20100166729A9 (en) * 2007-04-13 2010-07-01 Madison Edwin L Modified factor VII polypeptides and uses thereof
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
EP2268267B1 (en) 2008-04-21 2017-06-14 Novo Nordisk Health Care AG Dry transglutaminase composition
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
KR101792032B1 (ko) 2008-12-19 2017-11-02 백스터 인터내셔널 인코포레이티드 Ｔｆｐｉ 억제제 및 사용 방법
AU2011227714B2 (en) 2010-03-19 2014-09-04 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
BR112013002739A2 (pt) * 2010-08-05 2019-09-24 Council Scient Ind Res constructos de proteínas de fusão que possuem propriedades trombolíticas e anticoagulantes
CN109111505A (zh) 2012-03-21 2019-01-01 百深有限责任公司 Tfpi抑制剂及其使用方法
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
JP6559188B2 (ja) * 2017-07-06 2019-08-14 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018038398A (ja) * 2017-09-04 2018-03-15 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018108089A (ja) * 2018-02-19 2018-07-12 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP7444059B2 (ja) * 2018-07-25 2024-03-06 ソニーグループ株式会社 血液凝固系解析装置
JP6848016B2 (ja) * 2019-07-16 2021-03-24 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
CN114728044A (zh) 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221780A (en) * 1978-12-04 1980-09-09 Cort Joseph H Method for producing high potency factor VIII
JPH0780783B2 (ja) * 1985-11-26 1995-08-30 ノボ ノルディスク アクティーゼルスカブ 出血障害の治療のための第▲ＶＩＩ▼ａ因子を含有する治療組成物
US5622988A (en) * 1990-06-15 1997-04-22 Novo Nordisk A/S Use of a low molecular weight metabolite from fungus for reducing prolonged coagulation time
DK261490D0 (da) * 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
CA2121028A1 (en) * 1991-10-11 1993-04-15 Ulla K. E. Hedner Hemostatic composition for local hemostasis
AU3423493A (en) * 1991-12-31 1993-07-28 Zymogenetics Inc. Methods and compositions for reducing blood loss
AU4784693A (en) * 1992-07-24 1994-02-14 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
DE4429118C2 (de) * 1994-08-17 1997-01-16 Siemens Ag Radarsensor
WO1997029792A1 (en) * 1996-02-20 1997-08-21 Cohesion Corporation Tissue sealant compositions and methods of use thereof
AU7907398A (en) * 1997-06-23 1999-01-04 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
CA2318434A1 (en) * 1997-12-23 1999-07-01 Nuvas Llc Thrombogenic polypeptide chimeras and conjugates having activity dependent upon association with tumor vascular endothelium
WO1999058699A2 (en) * 1998-05-14 1999-11-18 Battelle Memorial Institute Transgenic plant-derived human blood coagulation factors
EP1148427A1 (en) * 2000-04-21 2001-10-24 Koninklijke KPN N.V. Method of and system for creating a button type bookmark in a web browser displaying a user-selected part of the corresponding data file
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US6825323B2 (en) * 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
US20030203845A1 (en) * 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
AU2002229510A1 (en) * 2001-02-05 2002-08-19 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor viii polypeptides
US20030119741A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and aprotinin polypeptides
US20060025336A1 (en) * 2001-07-16 2006-02-02 Novo Nordisk A/S Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
US7291587B2 (en) * 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
US7078479B2 (en) * 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
WO2003039585A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
EP1446148A1 (en) * 2001-11-09 2004-08-18 Novo Nordisk A/S Pharmaceutical composition comprising a factor vii polypeptide and epsilon-aminocapronic acid
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
JP2005526004A (ja) * 2001-11-09 2005-09-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよびトラネキサム酸を含む薬学的組成物
US20030119743A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
US20030124118A1 (en) * 2001-11-27 2003-07-03 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and protein S inhibitors

Also Published As

Publication number Publication date
US20030092627A1 (en) 2003-05-15
HUP0301868A3 (en) 2006-11-28
HUP0301868A2 (hu) 2003-08-28
US20070280920A1 (en) 2007-12-06
AU5822801A (en) 2001-11-20
EP1282439A1 (en) 2003-02-12
CN1304049C (zh) 2007-03-14
AU2001258230A1 (en) 2001-11-20
DE60112429T2 (de) 2006-06-01
US20060199766A1 (en) 2006-09-07
EP1282438A1 (en) 2003-02-12
DK1282438T3 (da) 2005-11-14
JP2003532684A (ja) 2003-11-05
ES2247106T3 (es) 2006-03-01
ATE311198T1 (de) 2005-12-15
IL152554A0 (en) 2003-05-29
DE60115422D1 (de) 2006-01-05
WO2001085199A1 (en) 2001-11-15
NO20025355D0 (no) 2002-11-08
DE60112429D1 (de) 2005-09-08
DE60115422T2 (de) 2006-08-17
EP1282439B1 (en) 2005-11-30
PL365042A1 (en) 2004-12-27
AU2001258228B2 (en) 2006-01-12
CN1429117A (zh) 2003-07-09
ES2254414T3 (es) 2006-06-16
ATE300953T1 (de) 2005-08-15
JP2004505016A (ja) 2004-02-19
NO20025355L (no) 2003-01-09
EP1282438B1 (en) 2005-08-03
CZ20023667A3 (cs) 2003-04-16
WO2001085198A1 (en) 2001-11-15
EP1593389A1 (en) 2005-11-09
CA2406583A1 (en) 2001-11-15

Similar Documents

Publication Publication Date Title
BR0110659A (pt) Composição farmacêutica, kit, uso de um fator viia em combinação com um fator, xiii, e, métodos para intensificação da formação de coágulo de fibrina em um indivìduo e para tratar de episódios de hemorragia em um indivìduo
BR9812965A (pt) Métodos para tratamento de estados hipercoaguláveis ou deficiência de proteìna c adquirida
BR0207006A (pt) Composição farmacêutica, kit, uso de uma preparação de um fator vii ou polipeptìdeo relacionado ao fator vii em combinação com uma preparação de um fator ix ou polipeptìdeo relacionado ao fator ix, uso de uma composição, método para tratar de episódios de hemorragia em um paciente, para reduzir o tempo de coagulação em um paciente, para intensificar a hemostasia em um paciente, para reduzir o número de administrações da proteìna do fator de coagulação necessário para deter a hemorragia e manter a hemostasia em um paciente, para reduzir a quantidade de proteìna do fator de coagulação administrada necessária para deter a hemorragia e manter a hemostasia de um paciente, para prolongar o tempo de lise do coágulo em um paciente, para aumentar a resistência do coágulo em um paciente, e para intensificar a formação de coágulo de fibrina em um paciente
BR0014384A (pt) Compostos para o tratamento da isquémia
BR9708632A (pt) Composto calcilìticos
ATE468889T1 (de) Kosmetische zusammensetzung zur behandlung von alternder und/oder gestresster haut
BR0014078A (pt) Inibidores de fator xa
BR0312275A (pt) Composição e método para tratamento de superfìcies ou de ar, superfìcie assim tratada e artigo de manufatura
BR0116832A (pt) Produto desodorante, método cosmético e método de fabricação de composição desodorante
DE50204766D1 (de) Verwendung von kreatin, kreatinin und/oder cyclokreatin zur stärkung und verbesserung der haarstruktur
BRPI0502346A (pt) processo de tratamento cosmético para prevenir e/ou tratar as peles sensìveis e/ou secas, utilização de uma quantidade eficaz de pelo menos um microorganismo notadamente probiótico e/ou uma de suas frações e/ou um de seus metabólitos e composição cosméticas e/ou dermatológica
BR0312165A (pt) Utilização da taurina para o tratamento da alopecia
PT1052905E (pt) Processo anti-germinativo de tuberculos e bolbos utilizando o eugenol e/ou o isoeugenol
BR0212907A (pt) Métodos para tratamento ou prevenção de inflamação vascular usando inibidor(es) da absorção de esteróis
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
ATE220918T1 (de) Matrixprotein enthaltende zusammensetzungen zur wundheilung
BR0213046A (pt) Anticorpo humano isolado, composição farmacêutica, composição, método para tratamento de um dustúrbio relacionado com fviia/tf em um ser humano, método para a preparação de um antocorpo humano, anticorpo humano, método para a preparação do mesmo, e, célula produtora do anticorpo humano
BRPI0414215A (pt) tienopirazóis
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR0211256A (pt) Composição farmacêutica, kit, usos de um polipeptìdeo relacionado ao fator vii ou fator vii em combinação com um polipeptìdeo relacionado ao fator xi ou fator xi e de uma composição, e, métodos para tratar de episódios de hemorragia em um paciente, para reduzir o tempo de coagulação em um paciente, para intensificar a hemostasia em um paciente, para prolongar o tempo de lise do coágulo e para aumentar a resistência do coágulo em um paciente
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
WO2003039453A3 (en) Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
ES2195655T3 (es) Procedimiento para tratar fiebre hemorragica virica con proteina c.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NOVO NORDISK HEALTH CARE AG (CH)

Free format text: TRANSFERIDO DE: NOVO NORDISK A/S

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO DA RPI 2016 DE 25/08/2009.